Germany cannabis legalization draws sharp criticism as experts say Ekocan interim report underplays youth risks
Germany cannabis legalization criticized by psychiatric and addiction societies after Ekocan interim report; experts warn of rising youth risks and gaps in care.
Germany’s partial cannabis legalization and the Ekocan interim evaluation are facing renewed scrutiny after three leading medical societies argued the report paints an overly optimistic picture. The Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN), the Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (DGKJP) and the Deutsche Gesellschaft für Suchtforschung und Suchttherapie (DG-Sucht) say the data do not yet justify reassurance about public-health impacts. Researchers involved in addiction medicine and child psychiatry say immediate policy adjustments and strengthened prevention are needed to protect adolescents and young adults.
Specialist societies dispute Ekocan interim findings
The three professional groups issued a joint statement arguing the Ekocan interim report understates emerging harms related to the part-legal market. They warn that policymakers and the public could interpret the interim results as a premature green light despite continuing warning signs from clinicians and hospitals. Mathias Luderer, head of addiction medicine at the University Hospital Frankfurt, outlined several methodological and practical concerns driving the societies’ critique.
Their objections center on interpretation rather than outright denial of Ekocan’s data, with the societies emphasizing that early signals—particularly from clinical practice—require a more cautious public assessment. They stress that evaluation is precisely intended to detect and correct unintended consequences quickly, and that the current findings leave important questions insufficiently addressed.
Short evaluation window weakens conclusions
A central point of contention is the limited time span covered by the interim evaluation. The law entered into force in April 2024, and experts note that two years of observation is too brief to capture medium-term shifts in consumption patterns and health outcomes. Luderer and others reference international experiences—Canada’s post-legalization period is often cited—where measurable changes in prevalence and harms commonly emerged over five to ten years.
Clinicians report rises in cannabis-related hospital admissions, acute intoxications and first-episode psychoses that may not be fully reflected in early population surveys. The societies caution that dependence and more chronic consequences tend to develop gradually, so present prevalence stability does not preclude future increases in problematic use.
Decline in judicial referrals and early-intervention uptake
The Ekocan report itself documents a marked reduction in referrals to early-intervention and prevention programs that previously resulted from police or judicial processing. Because cannabis possession is largely removed from the narcotics statute under the new law, mandatory referrals and court-ordered counseling have declined, and participation numbers for early-intervention initiatives have dropped accordingly. The professional societies say this creates a treatment gap precisely for a high-risk subgroup that had been reached through those former referral pathways.
The new law’s paragraph intended to address this—requiring youth welfare authorities only to “encourage” use of interventions when child welfare is at risk—was described by critics as vague and insufficiently coercive. For experts focused on young people, a reliance on voluntary uptake is unlikely to secure interventions for those most in need, they argue.
Treatment infrastructure under strain as major youth clinic faces closure
Compounding concerns about prevention and treatment access is the impending closure of a major rehabilitation facility for addicted children and adolescents. The Dietrich-Bonhoeffer-Klinik in Ahlhorn, which accounts for a significant share of inpatient youth addiction capacity nationally, is expected to close at the end of June. Medical societies warn that losing roughly 60 of the country’s juvenile addiction beds will materially reduce the healthcare system’s ability to respond if problematic use rises.
Clinicians caution that reduced inpatient capacity will translate into longer waits and fewer opportunities for intensive early treatment, particularly for complex cases involving co‑occurring psychiatric disorders. They see the timing as especially problematic given the simultaneous reduction in judicially mediated referrals.
Ekocan team defends methods and invites further dialogue
Jakob Manthey, project coordinator for the evaluation at the Centre for Interdisciplinary Addiction Research at the University of Hamburg, told reporters the Ekocan team has invited the specialist societies to contribute to data collection and discussion. Manthey said Ekocan will publish a formal response addressing the criticisms and intends to clarify the study’s data sources and limitations. The evaluation team rejects a claim that the evidence base is inadequate, but also acknowledges ongoing data collection and analysis.
Both sides frame their positions as complementary to some degree: Ekocan emphasizes current measurements and trends, while the medical societies emphasize the need for longer observation, targeted surveillance and rapid policy action where clinical practice indicates harm. The debate highlights tensions between early population surveillance and frontline clinical experience.
Experts and academic evaluators now call for strengthened monitoring, clearer preventive mandates for youth services, and contingency planning for treatment capacity if indicators of problematic use increase. The professional societies have asked policymakers to ensure that the evaluation mechanism leads to timely remedial measures rather than a prolonged wait-and-see posture.
The coming months will test whether the Ekocan evaluation process can reconcile population-level findings with clinical reports and deliver policy adjustments that protect young people while the new market stabilizes.
